PUBLIC COMPANY LIMITED 2019 04/02/2020 Finanacial Statements ( 22 record(s) found) Year Status Type Period As Of Audit Financial Statement MD&A Financial Statement Revise 2022 Consolidated Year 30/09
expenses 30 28 2 7% 8.0% 7.3% Finance costs 11 13 (2) -18% Share of loss from associate 0 - Income tax expense (1) 1 (3) Profit for the quarter 17 (7) 24 4.6% (1.8%) Consolidated financial information (Unit
costs 13.36 14.48 (1.12) -7.7% Income tax expense 1.45 2.06 (0.61) -29.6% Profit for the quarter (6.96) 9.32 (16.28) -174.6% (1.8%) 2.1% Consolidated financial information (Unit : Million Baht) For three
Bath 18.44 million. The operating results of the consolidated financial statement for the 3-month and 6-month period ended June 30, 2017 The Consolidated Financial Statement For the year period of (unit
Baht 104.65 million, decrease of selling and administration expenses of Bath 15.08 million and increase of corporate income tax of Bath 24.77 million. The operating results of the consolidated financial
. DOD017/2562 May 8, 2019 Re: Management’s Discussion and Analysis (MD&A) of the Consolidated Financial Results for Quarter 1 of 2019 To: The President The Stock Exchange of Thailand DOD Biotech Public
PERIOD OF THREE MONTHS ENDED SEPTEMBER 30, 2017 1. Analysis of operation results for the third quarter of 2017 in comparison with those for the same quarter of 2016 (from the consolidated financial
MARCH 31, 2018 1. Analysis of operation results for the fir st quarter of 2018 in compar ison with those for the same quar ter of 2017 (from the consolidated financial statements) Items First quarter of
: Million Baht) Consolidated financial statements Q2’ 2020 Q2’ 2019 % Change Sales and Service Income 333 511 -35 Other Revenue 8 4 100 Less Cost of Sales and Services 276 412 -33 Selling and Administrative